A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
Clinical trial NCT04576156 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04576156
- Sponsor
- Geron Corporation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-12
- Primary completion
- 2028-06-30
- Enrollment
- 327
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.